Forum to spotlight growth of railway sector in Saudi Arabia

Ammar bin Ahmed Al-Nahdi
Short Url
Updated 26 January 2020

Forum to spotlight growth of railway sector in Saudi Arabia

The Saudi Railway Company (SAR), in cooperation with the Ministry of Transport, is racing to prepare for the 2020 Railway Forum, to be held under the patronage of King Salman. The event has garnered the interest of ministers, leaders and influential figures in the transport industry from around the world. It is being considered as yet another achievement to be added to the Kingdom’s economic renaissance in various fields, the most important of which is the transport sector, which is one of the pillars of the Kingdom’s Vision 2030.

The forum, which will be held on Jan. 28 and 29 at the Ritz-Carlton hotel in Riyadh, seeks to showcase the latest findings of the railways and transportation industry, while expanding the horizons of cooperation between concerned international companies, and employing the capabilities required for the development and growth of the transport sector. It also aims to elaborate modern national programs to develop this industry.

The forum aims to shed light on the development and growth of the railway sector in the Kingdom, and to attract investments via local and global partnerships. It seeks to highlight the Kingdom’s role as a major center for transport services in the region. The event hopes to place the railways sector in the Kingdom on the global map, by creating a platform to exchange successful experiences, put forward distinctive ideas, learn about modern technologies in the railway sector, and meet with influential people.

Ammar bin Ahmed Al-Nahdi, director general of corporate communications and marketing at SAR, said: “The forum will witness on the first day a discussion session titled ‘Towards 2030,’ in which Saudi Minister of Transport Saleh bin Nasser Al-Jasser will take part with a group of transport ministers from around the world. It will be followed by the participation of CEOs from the most prominent international companies in another similar session.”


Sanofi conference spotlights type 2 inflammations

Updated 04 February 2020

Sanofi conference spotlights type 2 inflammations

Global health care company Sanofi recently organized a medical conference on type 2 inflammations, namely atopic dermatitis and severe asthma, at the Jeddah Hilton. The event, held under the auspices of the Saudi Allergy, Asthma and Immunology Society, included speakers from various health sectors who highlighted latest technologies and Saudi Food and Drug Authority-approved medicines to treat the diseases.
In his opening speech, Professor Abdullah Al-Angari, president of the Saudi Allergy, Asthma and Immunology Society, praised the society’s keenness to organize such important conferences to review the latest developments in type 2 inflammations, and to attract specialists from around the globe. “The scientific papers presented at the conference contribute to informing about the latest developments in treating these diseases. Sanofi Dupixent medication plays an important role in the treatment of the second type of immune inflammations, which include atopic dermatitis and severe asthma. The Kingdom of Saudi Arabia is among the few countries around the world that provide such a treatment for this disease,” he added.
Dr. Ahmed Siraj, general manager of Sanofi Saudi Arabia, said: “It is of utmost importance to develop cooperation between specialized Arab and international societies by exchanging experiences and knowledge and the latest developments in the treatment of the type 2 immune Inflammations, and the need to hold training courses for beginner Saudi doctors to hone their skills. The disease has several remarkable features, including its genetic aspects and family roots, its signs that include dry skin, allergy toward special types of food, sensitivity to exposure to dust and weather changes, etc., all of which must be taken into consideration when treating the disease.”
The two-day conference covered various topics, including the relationship between basic immunology and allergies, difficulties in dealing with type 2 immune inflammations, and the role of immune cells in disease and clinical trials, among others. Some local experiences with new Sanofi Biologic were also reviewed. The conference highlighted the best practices of treating type 2 immune inflammations from Canada and Saudi Arabia, where Professor Jason Lee conveyed the Canadian experience of immune diseases to the attendees.